Molecular profile-based adjuvant treatment for women with high-intermediate risk endometrial cancer (PORTEC-4a): results of a randomised, open-label, phase 3, multicentre, non-inferiority trial.

van den Heerik ASVM, Horeweg N, Haverkort MAD, Kuijsters N, Kommoss S, Koppe FLA, Nowee ME, Westerveld H, De Jong MAA, Frühauf F, Cnossen JS, Mens JWM, Beukema JC, Chargari C, Gillham C, Jurgenliemk-Schulz IM, Vandecasteele K, Hamann M, Kiderlen M, Staebler A, Nijman HW, Wortman BG, Asteinidou E, de Boer SM, van den Hout WB, Verhoeven-Adema KW, Nout RA, Putter H, Bosse T, Creutzberg CL.

Open source

DOI: 10.1016/s1470-2045(25)00612-6
Published: 2026-01-01
Container: Lancet Oncol
Publisher: Not recorded
Open access: no

Credibility signals

limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1016/s1470-2045-25-00612-6,
  title = {Molecular profile-based adjuvant treatment for women with high-intermediate risk endometrial cancer (PORTEC-4a): results of a randomised, open-label, phase 3, multicentre, non-inferiority trial.},
  author = {van den Heerik ASVM and  Horeweg N and  Haverkort MAD and  Kuijsters N and  Kommoss S and  Koppe FLA and  Nowee ME and  Westerveld H and  De Jong MAA and  Frühauf F and  Cnossen JS and  Mens JWM and  Beukema JC and  Chargari C and  Gillham C and  Jurgenliemk-Schulz IM and  Vandecasteele K and  Hamann M and  Kiderlen M and  Staebler A and  Nijman HW and  Wortman BG and  Asteinidou E and  de Boer SM and  van den Hout WB and  Verhoeven-Adema KW and  Nout RA and  Putter H and  Bosse T and  Creutzberg CL.},
  year = {2026},
  journal = {Lancet Oncol},
  doi = {10.1016/s1470-2045(25)00612-6},
  url = {https://doi.org/10.1016/s1470-2045(25)00612-6}
}

RIS

TY  - JOUR
TI  - Molecular profile-based adjuvant treatment for women with high-intermediate risk endometrial cancer (PORTEC-4a): results of a randomised, open-label, phase 3, multicentre, non-inferiority trial.
AU  - van den Heerik ASVM
AU  -  Horeweg N
AU  -  Haverkort MAD
AU  -  Kuijsters N
AU  -  Kommoss S
AU  -  Koppe FLA
AU  -  Nowee ME
AU  -  Westerveld H
AU  -  De Jong MAA
AU  -  Frühauf F
AU  -  Cnossen JS
AU  -  Mens JWM
AU  -  Beukema JC
AU  -  Chargari C
AU  -  Gillham C
AU  -  Jurgenliemk-Schulz IM
AU  -  Vandecasteele K
AU  -  Hamann M
AU  -  Kiderlen M
AU  -  Staebler A
AU  -  Nijman HW
AU  -  Wortman BG
AU  -  Asteinidou E
AU  -  de Boer SM
AU  -  van den Hout WB
AU  -  Verhoeven-Adema KW
AU  -  Nout RA
AU  -  Putter H
AU  -  Bosse T
AU  -  Creutzberg CL.
PY  - 2026
JO  - Lancet Oncol
DO  - 10.1016/s1470-2045(25)00612-6
UR  - https://doi.org/10.1016/s1470-2045(25)00612-6
ER  -

APA

ASVM, V. D. H., N, H., MAD, H., N, K., S, K., FLA, K., ME, N., H, W., MAA, D. J., F, F., JS, C., JWM, M., JC, B., C, C., C, G., IM, J., K, V., M, H., M, K., A, S., HW, N., BG, W., E, A., SM, D. B., WB, V. D. H., KW, V., RA, N., H, P., T, B., & CL., C. (2026). Molecular profile-based adjuvant treatment for women with high-intermediate risk endometrial cancer (PORTEC-4a): results of a randomised, open-label, phase 3, multicentre, non-inferiority trial.. Lancet Oncol. https://doi.org/10.1016/s1470-2045(25)00612-6

Source records

europe-pmc · retrieved 2026-09-26T18:53:57.755Z